Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients
NCT ID: NCT00600990
Last Updated: 2017-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
624 participants
INTERVENTIONAL
2004-12-31
2006-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting
NCT00108095
Effects of Ondansetron Dose and Timing on Post-operative Nausea and Vomiting
NCT03297021
A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)
NCT00231777
Association of 5-HT3 Receptor Gene Polymorphism With the Efficiency of Ondansetron for Postoperative Nausea and Vomiting
NCT01657786
A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)
NCT01507194
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GW597599
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Undergoing gynecological or gallbladder surgery.
18 Years
55 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Glendale, California, United States
GSK Investigational Site
Laguna Hills, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Pasadena, California, United States
GSK Investigational Site
Boca Raton, Florida, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
Omaha, Nebraska, United States
GSK Investigational Site
Albany, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Durham, North Carolina, United States
GSK Investigational Site
Raleigh, North Carolina, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Spokane, Washington, United States
GSK Investigational Site
St Leonards, New South Wales, Australia
GSK Investigational Site
Westmead, New South Wales, Australia
GSK Investigational Site
Carlton, Victoria, Australia
GSK Investigational Site
Melbourne, Victoria, Australia
GSK Investigational Site
Ringwood East, Victoria, Australia
GSK Investigational Site
Subiaco, Western Australia, Australia
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Ghent, , Belgium
GSK Investigational Site
Leuven, , Belgium
GSK Investigational Site
Victoria, British Columbia, Canada
GSK Investigational Site
Halifax, Nova Scotia, Canada
GSK Investigational Site
Greater Sudbury, Ontario, Canada
GSK Investigational Site
Kingston, Ontario, Canada
GSK Investigational Site
Oshawa, Ontario, Canada
GSK Investigational Site
Charlottetown, Prince Edward Island, Canada
GSK Investigational Site
Chandler, Quebec, Canada
GSK Investigational Site
Regina, Saskatchewan, Canada
GSK Investigational Site
Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
Brno, , Czechia
GSK Investigational Site
Jihlava, , Czechia
GSK Investigational Site
Olomouc, , Czechia
GSK Investigational Site
Ostrava - Poruba, , Czechia
GSK Investigational Site
Helsinki, , Finland
GSK Investigational Site
Kuopio, , Finland
GSK Investigational Site
Roosendaal, , Netherlands
GSK Investigational Site
Rotterdam, , Netherlands
GSK Investigational Site
Rotterdam, , Netherlands
GSK Investigational Site
Poznan, , Poland
GSK Investigational Site
Warsaw, , Poland
GSK Investigational Site
Warsaw, , Poland
GSK Investigational Site
Arcadia, Pretoria, , South Africa
GSK Investigational Site
Bloemfontein, , South Africa
GSK Investigational Site
Istanbul, , Turkey (Türkiye)
GSK Investigational Site
Istanbul, , Turkey (Türkiye)
GSK Investigational Site
Chelmsford, Essex, United Kingdom
GSK Investigational Site
Northampton, Northamptonshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NKO101287
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.